Starling Oncology, Inc.
- STLN ยท Nasdaq
- Services-Offices & Clinics of Doctors of Medicine
- Cerritos, CA
- 641 employees
- CIK 0001799191
Updated from SEC filings through
Top things to know
Executives
-
Daniel Virnich Chief Executive Officer 4, 2026-05-22 - Robert Ross Carter Chief Financial Officer 4, 2026-05-22
- Robert Carter Chief Financial Officer 10-K, 2026-03-12
-
Yale Podnos Chief Medical Officer 4, 2026-07-16 - Jeffrey Langsam Chief Clinical Officer 4, 2026-04-23
- Kristin England Chief Administrative Officer 4, 2026-04-23
Starling Oncology, Inc. is a U.S. public company in services-offices & clinics of doctors of medicine (SIC 8011), headquartered in Cerritos, CA. It trades as STLN on Nasdaq. Revenue was $503M in the fiscal year ending December 31, 2025, +27.8% from the year before. It reported about 641 employees. Daniel Virnich is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $503M 10-K, 2026-03-12 | $393M 10-K, 2026-03-12 | $324M 10-K, 2025-03-26 | $252M 10-K, 2024-03-28 | $203M 10-K, 2023-03-16 |
| Operating income | -$36.1M 10-K, 2026-03-12 | -$60.1M 10-K, 2026-03-12 | -$77.0M 10-K, 2025-03-26 | -$82.0M 10-K, 2024-03-28 | -$45.9M 10-K, 2023-03-16 |
| SG&A | $106M 10-K, 2026-03-12 | $108M 10-K, 2026-03-12 | $114M 10-K, 2025-03-26 | $120M 10-K, 2024-03-28 | $83.4M 10-K, 2023-03-16 |
| Net income | -$60.6M 10-K, 2026-03-12 | -$64.7M 10-K, 2026-03-12 | -$83.1M 10-K, 2025-03-26 | $152K 10-K, 2024-03-28 | -$10.9M 10-K, 2023-03-16 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Daniel Virnich Chief Executive Officer at The Oncology Institute (NASDAQ: TOI) | Chief Executive Officer | 4, 2026-05-22 |
| Robert Ross Carter CFO, Starling Oncology | Chief Financial Officer | 4, 2026-05-22 |
| Robert Carter | Chief Financial Officer | 10-K, 2026-03-12 |
| Yale Podnos | Chief Medical Officer | 4, 2026-07-16 |
| Jeffrey Langsam | Chief Clinical Officer | 4, 2026-04-23 |
| Kristin England | Chief Administrative Officer | 4, 2026-04-23 |
| Anne McGeorge | Director | 10-K, 2026-03-12 |
| Brad Hively | Director | 10-K, 2026-03-12 |
| Karen Johnson | Director | 10-K, 2026-03-12 |
| Kimberly Tzoumakas | Director | 10-K, 2026-03-12 |
| Mark Pacala | Director | 10-K, 2026-03-12 |
| Mark Stolper | Director | 10-K, 2026-03-12 |
| Mohit Kaushal | Director | 10-K, 2026-03-12 |
What Starling Oncology, Inc. does
Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 102.0 million (as of November 3, 2026) | 10-Q, November 6, 2026 |
|---|---|---|
| Public float | $137M (as of June 30, 2025) | 10-K, March 12, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, November 6, 2026 |
| Latest proxy statement | Meeting June 17, 2026 (filed April 30, 2026) | DEF 14A, April 30, 2026 |
| Auditor | Bdo Usa, P.c. (Costa Mesa, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 21, 2026 | Brad Hively Director | Sale | 298,853 | $1.9M | Form 4, August 24, 2026 |
| July 14, 2026 | Yale Podnos Chief Medical Officer | Sale | 23,452 | $150K | Form 4, July 16, 2026 |
| June 8, 2026 | Yale Podnos Chief Medical Officer | Sale | 23,451 | $126K | Form 4, June 9, 2026 |
| April 16, 2026 | Mohit Kaushal Director | Sale | 95,719 | $335K | Form 4, April 16, 2026 |
| January 2, 2026 | Robert Ross Carter Chief Financial Officer | Sale | 247 | $879.32 | Form 4, January 5, 2026 |
| December 15, 2025 | Brad Hively Director | Sale | 13,333 | $50K | Form 4, December 16, 2025 |
| November 18, 2025 | Mark L. Pacala Director | Sale | 50,000 | $200K | Form 4, November 20, 2025 |
| September 4, 2025 | Growth I. L.P. M33 Director | Sale | 6,700,000 | $20.7M | Form 4, September 5, 2025 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-02
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-21
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-03
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-07
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-18
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-22
- Item 1.05 Material cybersecurity incident
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-13
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Starling Oncology, Inc.
- What does Starling Oncology, Inc. do?
- In its own words, from Item 1 of its 10-K: "Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients."
- What is Starling Oncology, Inc.'s revenue?
- $503M for the fiscal year ending December 31, 2025, from its 10-K filed March 12, 2026.
- Is Starling Oncology, Inc. profitable?
- Starling Oncology, Inc. reported net income of -$60.6M for the fiscal year ending December 31, 2025.
- How many employees does Starling Oncology, Inc. have?
- About 641 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Starling Oncology, Inc.?
- Daniel Virnich, Chief Executive Officer, as named in a 4 filed May 22, 2026.
- Who is the CFO of Starling Oncology, Inc.?
- Robert Ross Carter, Chief Financial Officer, as named in a 4 filed May 22, 2026.
- Where is Starling Oncology, Inc. headquartered?
- Cerritos, CA.
- What is Starling Oncology, Inc.'s stock ticker?
- STLN, DFPH, STLNW on Nasdaq.
- What industry is Starling Oncology, Inc. in?
- Services-Offices & Clinics of Doctors of Medicine, SIC code 8011.
- What is Starling Oncology, Inc.'s website?
- theoncologyinstitute.com.
- When does Starling Oncology, Inc. report earnings next?
- November 12, 2026. Source: ir_event.
- Is Starling Oncology, Inc. a public company?
- Yes. Starling Oncology, Inc. files with the SEC under CIK 0001799191 and trades as STLN.
- Who audits Starling Oncology, Inc.?
- Bdo Usa, P.c., Costa Mesa, California, as named in its latest annual report (10-K).
- How many shares of Starling Oncology, Inc. are outstanding?
- 102.0 million shares as of November 3, 2026, from its 10-Q filed November 6, 2026.
- What is Starling Oncology, Inc.'s public float?
- $137M as of June 30, 2025, as reported on the cover of its 10-K filed March 12, 2026.
- How many business segments does Starling Oncology, Inc. report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 6, 2026.
- When is Starling Oncology, Inc.'s annual shareholder meeting?
- June 17, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.
- Have Starling Oncology, Inc. insiders traded stock recently?
- Since August 19, 2025, officers and directors reported 11 open-market sales worth about $65.0M and 0 purchases on Forms 4 and 5. The most recent: Brad Hively (Director) sold 298,853 shares on August 21, 2026.